Leading Article

The treatment of hypertension in the elderly

Miriam Chellingsworth¹ and D.G. Beevers²

¹Department of Clinical Pharmacology and Therapeutics, Queen Elizabeth Hospital, Birmingham, and ²Department of Medicine, Dudley Road Hospital, Birmingham, UK.

Many important issues relating to the treatment of mild and modern hypertension in the elderly remain to be resolved. However, the results of the European Working Party on Hypertension in the Elderly trial have answered some questions, and will probably change the views of many on the treatment of hypertension in the elderly patients (Amery et al., 1985).

The size of the problem

This is difficult to measure until a working definition of high blood pressure for the elderly is defined. Cross-sectional studies have shown blood pressure to rise with age at least until the age of 70. The average diastolic blood pressure then falls (Anderson & Cowan, 1959; Master et al., 1958), but systolic pressure continues to rise. Some longitudinal studies have shown a less marked effect of age (Kannel et al., 1981) and, in some primitive populations, blood pressure does not rise with age at all. The World Health Organization has defined hypertension as a blood pressure greater than 160/95 mmHg (World Health Organisation, 1978); the Framingham study also used this definition. If a single, casual blood pressure reading of 160/95 mmHg is taken, then the prevalence of hypertension approaches 50% in some elderly populations, with a further 13% having isolated systolic hypertension (Cholandrea et al., 1970). However, if a series of measurements is taken these figures fall dramatically (Wing et al., 1982). The value of treating a person with hypotensive drugs after only one raised blood pressure reading is not known, yet most epidemiological studies relating prognosis to blood pressure are based on single casual readings.

Systolic hypertension

Isolated or disproportionate systolic hypertension is commoner in the elderly. Studies have shown it to be an important risk factor in the development of complications, particularly stroke (Kannel et al., 1981). The best treatment for systolic hypertension is not yet known, though the sub-group with low renin levels may respond well to thiazide diuretics (Niarchos & Laragh, 1984). Studies of the orally active angiotensin converting enzyme inhibitor, enalapril, suggest that this class of drug is better at reducing systolic blood pressure than beta-blockers or thiazides (Enalapril in Hypertension Study Group, 1984). The pathogenesis of isolated systolic hypertension is thought to be the increasing arterial rigidity and decreasing arterial compliance in old age (Simon et al., 1979), though this is by no means certain. There is as yet no published trial of the treatment of isolated systolic hypertension although one group has shown that control of systolic blood pressure in the elderly with systolic/diastolic hypertension reduced the incidence of adverse effects (Applegate et al., 1982). A randomized controlled trial of the treatment of isolated systolic hypertension is currently under way in the USA but results are not expected for at least 5 years.

Effect of blood pressure on morbidity and mortality in the elderly

Some British studies have failed to show any relationship between hypertension and excess morbidity and mortality in the elderly (Hodkinson & Exton-Smith, 1976; Evans, 1983; Droller et al., 1952; Anderson & Cowan, 1976), particularly in those over 80 years. Some have even suggested a protective effect of hypertension in the elderly (Rajala et al., 1983). These findings seem odd in the face of the fact that hypertension is known to have adverse effects in younger

Correspondence: M. Chellingsworth, B.M., M.R.C.P., Accepted: 10 September 1985

© The Fellowship of Postgraduate Medicine, 1986
patients (Hypertension Detection and Follow-up Cooperative Group, 1982). There may be a tendency for those individuals at risk of dying from their hypertension to do so before reaching old age. However, this cannot be the whole explanation, as large trials are now beginning to show a reduction in morbidity and mortality in those elderly people whose hypertension is treated.

**Summary of the early trials involving elderly patients**

In 1968, Priddle and co-workers (1968) in a study of elderly hypertensives in Toronto, showed a reduced mortality rate in the treated patients. However, the study was small, and not randomized or double-blind.

The Veterans Administration Cooperative Study on Antihypertensive Agents (1972) showed that, in patients over 50 years of age with cardiovascular or renal abnormalities who had a diastolic blood pressure of 90–104 mmHg the treatment of hypertension significantly reduced cardiovascular complications. However, it is always unsafe to look only at small subgroups in a trial that was not designed specifically for the elderly, so the results are not conclusive.

The National Heart Foundation of Australia study (1981) of mild hypertension included 582 subjects aged 60 to 69 years at entry. Their diastolic blood pressures were between 95 and 109 mmHg. Half were randomized to receive active treatment, and, in this group there was a 39% ($P < 0.025$) reduction in death and cardiovascular events. The trial did not contain enough patients to be certain of the benefits of treatment in the elderly, which was also a sub-group of a larger study of mild hypertension.

The highly controversial Hypertension Detection and Follow-Up Program (Hypertension Detection and Follow-up Cooperative Group, 1982) was also a significant reduction in mortality in the sub-group aged 60 to 69 who were randomized to 'stepped care' of their hypertension rather than those referred to the care of their family practitioners.

The first results of the MRC trial of treatment of mild hypertension have recently been published (MRC Working Party, 1985). However, no patient older than 64 years was entered into the study, and, as yet, the mortality and morbidity in different age groups has not been revealed.

**The European Working Party on Hypertension in the Elderly**

The EWPHE study is a large, multicentre, double-blind, randomized trial, specifically designed to show the effects of treatment of mild hypertension in patients of 60 to 100 years of age (mean age 72 years). Because it was started in the early 1970s the treatment regimen chosen (hydrochlorothiazide and triamterene, with methyldopa added if necessary) is now rather outdated. The trial has now been terminated because of a significant (36%) reduction in cardiovascular events in the treatment group. Cardiovascular mortality was also reduced, as were cerebrovascular 'events' but not cerebrovascular mortality (Amery et al., 1985). There was no significant difference in overall mortality in treated or control patients. This is not unexpected because as soon as a reduction in cardiovascular mortality was shown, the trial was terminated. There was a 26% reduction in total mortality in the treated group, and, if the trial had been continued for longer, this difference might have become significant.

The reduction of cerebrovascular events is important as in elderly people stroke-free survival may be more important than just prolongation of life. The reduction in cardiovascular mortality is significant: this has not been shown in other trials of treatment of mild hypertension. It is surprising then, that it should be found in the elderly – a group who would already be expected to have developed atherosclerosis. The mechanism of this 'cardioprotection' by antihypertensive drugs is, therefore, open to question.

Although minor changes in biochemistry (mild hypokalaemia and slight increases in blood glucose and serum uric acid) were seen, no significant increase in adverse effects was noted in the active treatment group, and the drugs used appeared to be well tolerated (European Working Party on Hypertension in the Elderly, 1983). The initial report of EWPHE does not provide any information on the benefits of treating hypertension in the various age groups over the age of 60 years but when the sub-group analyses do become available, great care must be exercised in their interpretation. However, we do need to know whether the benefits of antihypertensive treatment are the same in patients of 60 to 70 years as in those of 70 to 80 years or even those of 80 to 90 years. Most EWPHE patients were hospital attenders and they are not, therefore, typical of fit, ambulant, hypertensive patients who are not hospital attenders. The British General Practice trial of treatment of hypertension in the elderly to be published later this year (Coope, 1982), should give the results of treating a more typical group of elderly hypertensives. Any group of elderly hypertensives will be very heterogeneous – some will be fit, some not, some frail, some strong. The EWPHE trial cannot be extrapolated to all patients of 60 years of age or more.

In summary, the EWPHE trial has shown a significant reduction in adverse cardiovascular events in the treated group. This, and several other studies have therefore shown that treatment of hypertension in the elderly is safe and worthwhile. The actively treated groups do not contain an excess number of 'drop-outs'
due to treatment side effects (European Working Party on Hypertension in the Elderly, 1983).

Choice of drug for the elderly hypertensives

There is relatively little information specifically on treatment of the elderly with hypotensive drugs. However, this should soon change following recent recommendations of the Committee on Safety of Medicines (Committee on Safety of Medicines Update, 1985), that new drugs should be tested in the elderly before being licensed.

Diuretics

The EWHPE and several other trials have confirmed the safety and efficacy of thiazide diuretics in elderly hypertensives. However, they are not without their problems; serum potassium levels should be checked, and especially in those who are also receiving digoxin, potassium supplements or potassium sparing agents are needed. Diabetes mellitus, hyperlipidaemia, gout, urinary incontinence and prostatism, all of which are commoner in the elderly, are relative contraindications.

β-adrenergic blockers

Blockers are widely used and well tolerated in most elderly patients (Hamdy et al., 1982; Hosie et al., 1983). There is, however, some evidence that these drugs are less effective in older patients (Schocken & Roth, 1977) although this has not been formally investigated. The pharmacokinetics of propranolol and metoprolol (Schneider et al., 1980; Schneck et al., 1980; Quarterman et al., 1981) are probably little altered in fit elderly people, but this does not apply to hospitalized patients (Castleden & George, 1979). Water soluble drugs such as atenolol which are mainly excreted by the kidney may reach much higher blood levels in the elderly, and should, in theory, be given in reduced dosage (Kurch & Gorg, 1982) although, in practice, higher doses are tolerated (O’Callaghan et al., 1983). Beta-blockers have been found to protect against the hypokalaemic effect of thiazides (Coope, 1982). Labetalol, a combined alpha- and beta-blocker is well tolerated and effective in the elderly in small doses (Eisalo & Virta, 1982). Of course, contraindications which apply in young patients also apply in the elderly, and a large number of elderly patients are excluded from treatment because of the high incidence of chest and peripheral vascular disease in this age group.

Centrally acting drugs

Methyldopa has been proved to be effective in the EWPHE trial. However, it is no longer the drug of first choice in young patients because of its central side effects (sedation and depression) and the occasional occurrence of haemolytic anaemia.

Clonidine is also effective in the elderly and in systolic hypertension (Weber et al., 1983), but is no longer widely used because of the rebound hypertensive effect on missing a dose. This may be very important in the forgetful elderly patient.

Reserpine

Reserpine, an adrenergic blocking drug has been advocated for treatment of the elderly hypertensive (Luxenberg & Feigenbaum, 1983). However, it is not widely used in the UK, because of a high incidence of depression and even suicide. It is, however, widely used in the USA and when given in low doses and at night may be well tolerated.

Vasodilators

Theoretically these are the drugs of choice in the elderly with predominant systolic hypertension, but there have been no large trials to prove this point. Prazosin has been used with good effect in the elderly but requires careful clinical supervision because of occasional severe postural hypotension after the first dose. The initial dose should be small, but can be increased quite rapidly.

Hydralazine is well tolerated in the elderly. Its metabolism by acetylation (Farah et al., 1977) in the liver is little affected by age. As in younger patients, it may cause a syndrome resembling systemic lupus erythematosus. One small short-term trial has shown that nifedipine is effective and generally well tolerated in the treatment of hypertension in the elderly, including those with isolated systolic hypertension (Stessmann et al., 1985), and it has been claimed that it is more effective in older patients (Buhler, 1983).

The angiotensin converting enzyme (ACE) inhibitors have not been assessed in the elderly, but possible beneficial effects, particularly on systolic pressures, makes this group theoretically attractive. However, in patients already receiving diuretic therapy, who may be volume depleted, great caution should be exercised, as ACE inhibitors may cause a precipitate drop in blood pressure. As plasma renin levels are lower in older patients (Niarchos & Laragh, 1984), in theory the ACE inhibitors might be less effective, but there is little information on this point.

In summary, the EWPHE trial has shown a significant reduction in cardiovascular events and mortality, a significant reduction in cerebrovascular
events, and a non-significant reduction in cerebrovascular mortality in patients over 60 with mild to moderate hypertension. Perhaps because the trial was terminated early, only a non-significant reduction in total mortality occurred in the treated group. For the first time, a small but significant benefit from treating hypertensives over age 60 has been shown: the large size of the problem makes the financial consequences of this enormous. Present evidence does, however, suggest that the elderly with repeated high blood pressure readings should be treated, and that they can be treated safely. Ideally, the EWPHE trial would be repeated using more up-to-date therapeutic agents but clearly the results of such a study would not be available for many years.

References


The treatment of hypertension in the elderly.

M. Chellingsworth and D. G. Beevers

doi: 10.1136/pgmj.62.723.1

Updated information and services can be found at:
http://pmj.bmj.com/content/62/723/1.citation

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/